Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent

NCT04844749 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT04844749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04844749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Lead sponsor
Veru Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 24, 2021
Completion date
May 4, 2023
Enrollment
105 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

androgen resistant prostatic cancer, metastatic castration-resistant prostate cancer